• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Evolving genetic testing and treatment pathways in non-small cell lung carcinoma: a Healthcare Professional survey of current practices in the UK

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Baijal, S.
    Crosbie, P.
    Fenemore, Jackie
    Desai, K.
    Affiliation
    University Hospital Birmingham NHS Trust, Birmingham
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    The treatment of non-small cell lung carcinoma (NSCLC) has changed significantly in recent years with the discovery of new oncogenic mutations and the introduction of immunotherapy. In March-June 2021 we conducted 57 interviews with healthcare professionals (HCPs) involved in the secondary care management of patients with NSCLC (39 oncologists, 10 nurses, 5 pathologists, 3 respiratory physicians) representing geographically dispersed NHS Trusts across the UK. The aim was to understand the current UK NSCLC patient pathway in relation to oncogenic mutation testing practices, treatment preferences as well as anticipated future trends. In terms of genetic testing, a variety of tests were commonly performed although the testing location varied. 47% (n=27) of respondents represented hospitals that performed genetic testing onsite, 30% (n=17) offsite, and 23% (n=13) at a genomic laboratory hub. Genetic tests perceived to be clinically relevant despite not currently being accessible or reimbursed included MET and HER-2 (Fig. 1). In terms of treatment preferences, in an adjuvant setting, respondents (n=46) estimated a median of 20.0% (IQR 10.0%-30.0%) of eligible patients decline chemotherapy despite being fit enough to receive it. Declining treatment in metastatic NSCLC was estimated to be 17.5% (10.0%-30.0%; n=46) for second/third line treatment. The most common reason for declining treatment was perception on impact on quality of life (89%, n=50/56). The survey highlights variance in mutation testing practices across the UK, which may impact diagnosis and treatment decisions, and in turn may contribute to health outcome inequalities. Molecular driven treatments tend to be better tolerated; as biomarker testing expands and targeted options become available, more patients may be willing to accept treatment. Insights suggest that future areas of clinical interest in NSCLC are MET, HER-2, KRAS and personalised neo/ adjuvant therapies. The survey results conclude there are a number of areas of unmet need remaining within the NSCLC patient pathway.
    Citation
    Baijal S, Crosbie P, Fenemore J, Desai K. Evolving genetic testing and treatment pathways in non-small cell lung carcinoma: a Healthcare Professional survey of current practices in the UK. Vol. 165, Lung Cancer. Elsevier BV; 2022. p. S5.
    Journal
    Lung Cancer
    URI
    http://hdl.handle.net/10541/625236
    DOI
    10.1016/S0169-5002(22)00056-3
    Additional Links
    https://dx.doi.org/10.1016/S0169-5002(22)00056-3
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0169-5002(22)00056-3
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.